Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96
The purpose of this study is to evaluate the safety and effectiveness of autologous gp96 treatment of gastric cancer.
Gastric Carcinoma
BIOLOGICAL: autologous gp96 vaccination|DRUG: Oxaliplatin+S-1
Disease free survival, 2 years|Number of participants with adverse events related to gp96 immunotherapy, A complete blood count will be requested before the first vaccination, after the second vaccination and after the last vaccination to monitor the side effect of gp96 immunotherapy. And blood chemistries will also be requested at the same time point for the same reason.

And other adverse events related to gp96 immunotherapy will be recorded according to the NCI-CTCAE 3.0 criteria., participants will be followed from the day of the first vaccination to the 30th day after the last vaccination.
Changes in antigen specific T cells, Tumor antigen specific T cells will be determined by IFN-Î³ Enzyme-linked immunosorbent spot using the autologous tumor cell lysis as the antigen., within 3 days before the first vaccination and within 3 days after the 10th vaccination|Overall survival, 3 years
The purpose of this study is to evaluate the safety and effectiveness of autologous gp96 treatment of gastric cancer.